株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

高血糖症:パイプライン分析

Hyperglycemia - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 253660
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
高血糖症:パイプライン分析 Hyperglycemia - Pipeline Review, H1 2016
出版日: 2016年06月08日 ページ情報: 英文 44 Pages
概要

高血糖症とは、血糖値が異常に高くなった時に起こる症状です。原因として、食べ物や運動の選択、病気、非糖尿病治療薬、あるいは十分なグルコース低下薬を摂取していないことなどが挙げられます。症状は頻尿、視力障害、疲労性頭痛、吐き気・嘔吐、ドライマウス、昏睡、混乱状態などがあります。治療法には抗高血糖治療およびインスリン治療があります。

当レポートでは、世界各国での高血糖症(過血糖症)治療法のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

高血糖症の概要

治療薬の開発

  • 高血糖症向けパイプライン製品の概要
  • 高血糖症向けパイプライン製品の比較分析

各企業で開発中の高血糖症治療薬

大学/研究機関で研究中の高血糖症治療薬

パイプライン製品の概略

  • 治験段階にある製品
  • 初期段階にある製品

高血糖症治療薬:開発中の製品の一覧(企業別)

高血糖症治療薬:研究中の製品の一覧(大学/研究機関別)

高血糖症治療薬の開発に従事している企業

  • キッセイ薬品工業
  • 田辺三菱製薬
  • PhaseBio Pharmaceuticals, Inc.

高血糖症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投薬経路別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

高血糖症治療薬:最新のパイプライン製品

高血糖症治療薬:開発が休止状態の製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8203IDB

Summary

Global Markets Direct's, 'Hyperglycemia - Pipeline Review, H1 2016', provides an overview of the Hyperglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperglycemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperglycemia
  • The report reviews pipeline therapeutics for Hyperglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperglycemia therapeutics and enlists all their major and minor projects
  • The report assesses Hyperglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperglycemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperglycemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperglycemia Overview
  • Therapeutics Development
    • Pipeline Products for Hyperglycemia - Overview
    • Pipeline Products for Hyperglycemia - Comparative Analysis
  • Hyperglycemia - Therapeutics under Development by Companies
  • Hyperglycemia - Therapeutics under Investigation by Universities/Institutes
  • Hyperglycemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hyperglycemia - Products under Development by Companies
  • Hyperglycemia - Products under Investigation by Universities/Institutes
  • Hyperglycemia - Companies Involved in Therapeutics Development
    • Kissei Pharmaceutical Co., Ltd.
    • Mitsubishi Tanabe Pharma Corporation
    • PhaseBio Pharmaceuticals, Inc.
  • Hyperglycemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CDR-267F018 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FGH-10019 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KR-62980 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PE-0139 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides to Antagonize Glucagon Receptor for Type 2 Diabetes and Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PEPCK for Type 2 Diabetes and Hyperglycemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hyperglycemia - Recent Pipeline Updates
  • Hyperglycemia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperglycemia, H1 2016
  • Number of Products under Development for Hyperglycemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hyperglycemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hyperglycemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Hyperglycemia - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Hyperglycemia, H1 2016
  • Number of Products under Development for Hyperglycemia - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top